Hepcludex (bulevirtide) FDA approval: what the peptide drug’s label actually establishes

01

What FDA approved—and what it did not

FDA approved Hepcludex (bulevirtide-gmod) injection for adults with chronic hepatitis delta virus infection who either do not have cirrhosis or have compensated cirrhosis. HDV infection occurs only in people with hepatitis B virus infection. The approval is therefore not a general hepatitis treatment, a wellness indication, or an approval for people with decompensated liver disease.

The product record matters as much as the ingredient name. FDA’s Purple Book identifies Hepcludex as a prescription biological product licensed under section 351(a), with BLA number 761468, a single-dose vial presentation, and an original approval date of May 22, 2026. Those details define a particular sponsor, manufacturing application, presentation, and label.

Calling bulevirtide a peptide does not extend the decision to the peptide category. A compounded preparation, research product, imported product, or clinic-branded program would require its own regulatory analysis. A seller cannot turn another product into Hepcludex by using the active ingredient’s name or saying it uses similar chemistry.

02

Accelerated approval is real approval with an unresolved clinical question

Hepcludex is FDA-approved, not investigational, for the labeled indication. It was approved through the accelerated-approval pathway, which permits approval for serious conditions based on an endpoint reasonably likely to predict clinical benefit while confirmatory evidence is completed. Describing the product as merely experimental would be inaccurate; describing long-term clinical benefit as already verified would also be inaccurate.

The prescribing information says the approval was based on a decrease in HDV RNA together with normalization of alanine aminotransferase, or ALT. It also states that improvement in disease-related clinical outcomes has not been established and that continued approval may depend on confirmatory evidence. Those limitations belong beside any efficacy statement, not hidden after promotional claims.

FDA’s approval letter requires an observational study comparing treated patients with a historical standard-of-care control group. The planned outcomes include development of cirrhosis, hepatic decompensation, liver transplantation, liver cancer, and liver-related death. The letter lists study completion in 2033 and a final report in 2034, so the evidence obligation is long term.

03

What the phase 3 evidence showed

The MYR301 phase 3 study was randomized, multicenter, open-label, and used a delayed-treatment comparison. FDA reported that 48% of participants in the immediate-treatment group met the combined response at week 48, compared with 2% in the delayed-treatment group. The combined endpoint required either undetectable HDV RNA or a decline of at least 2 log10 from baseline together with ALT normalization.

FDA also reported that 20% of the immediate-treatment group had undetectable HDV RNA at week 48, compared with none in the delayed-treatment group. Longer follow-up in that group showed higher proportions with undetectable RNA at weeks 96 and 144. These are group results under a clinical-trial protocol; they do not predict an individual response.

The published trial and label should be read together. The endpoint captures virologic and biochemical changes, while the confirmatory requirement asks whether those changes translate into outcomes people experience over time. The open-label design, defined population, and delayed-treatment comparison also limit casual comparisons with other products or care settings.

04

Safety information is central, not an afterthought

The label includes a boxed warning that severe acute exacerbations of hepatitis D and hepatitis B may occur after Hepcludex is discontinued. It identifies particular concern for people with cirrhosis and calls for close clinical and laboratory follow-up after discontinuation. This article reports the warning; it does not tell a reader to start, stop, or alter treatment.

FDA’s announcement lists hypersensitivity reactions, including anaphylaxis, as well as injection-site reactions, headache, abdominal pain, fatigue, and itching among possible adverse effects. The label also discusses drug interactions and populations for which evidence is limited. A short provider advertisement cannot substitute for the full current prescribing information.

Symptoms, laboratory changes, and treatment decisions require an appropriately licensed clinician familiar with hepatitis B and D. Seek urgent medical care for a suspected emergency. A directory cannot diagnose a liver problem, interpret an individual viral load, or decide whether the labeled product is appropriate.

05

How to verify a provider’s Hepcludex claim

Start with the exact finished product. Ask whether the provider means the FDA-licensed Hepcludex vial or another product described with the word bulevirtide. Match the proprietary name, proper name, BLA number, presentation, dispensing source, and current label. A peptide seller, bulk-ingredient certificate, or compounded-drug label is not the Purple Book record.

Next, verify clinical scope. The provider should accurately identify chronic HDV, the labeled adult population, and the accelerated-approval limitation. Claims about curing hepatitis, preventing every liver complication, treating uninfected people, reversing decompensated cirrhosis, or proving benefits for unrelated peptides go beyond the cited approval.

Finally, research the care pathway: who confirms the diagnosis, who manages the underlying hepatitis B infection, which clinician prescribes, how monitoring is handled, and where the prescription is dispensed. Do not infer access, insurance coverage, or individual suitability from FDA approval alone.

• →Exact branded product and BLA record
• →Current prescribing information
• →Labeled population and indication
• →Accelerated-approval endpoint and confirmatory obligation
• →Prescriber identity and relevant licensure
• →Dispensing pharmacy and follow-up process

06

What this approval teaches about peptide research

Hepcludex demonstrates why approval claims should be product-specific. FDA evaluated a defined peptide sequence, finished presentation, manufacturing application, indication, trial program, safety profile, and label. None of those findings automatically transfers to a substance that shares a pathway, amino-acid motif, or marketing category.

It also shows why databases serve different jobs. The Purple Book confirms the licensed biologic record; the label defines the approved use and warnings; the approval letter states the accelerated-approval and postmarketing conditions; and the peer-reviewed trial describes the study. A provider claim is stronger only when all of those records point to the same product.

Readers should revisit dynamic records rather than treating this publication date as permanent. Labels, postmarketing requirements, safety communications, and approval status can change. Treatment questions belong with appropriately licensed clinicians using the latest official information.